查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112599

噬菌體療法市場：依目標疾病、給藥途徑、目標細菌及地區分類－趨勢與預測至2035年

Bacteriophage Therapy Market by Target Indication, Route of Administration, Targeted Bacteria, and Geographical Regions - Trends and Forecast Till 2035
出版日期: | 出版商: Roots Analysis | 英文 221 Pages | 商品交期: 7-10個工作天內

價格

噬菌體療法市場概覽

全球噬菌體療法市場預計將從今年的 6,650 萬美元成長到 2035 年的 2.668 億美元，預測期內的複合年成長率約為 16.7%。

噬菌體療法市場-IMG1

噬菌體療法市場：成長與趨勢

抗菌素抗藥性（AMR）的快速蔓延，加速了開發新型抗感染疾病策略的必要性，以應對那些對傳統抗生素不再有效的感染疾病。世界衛生組織（WHO）估計，AMR每年直接導致約127萬人死亡，如果不採取行動，預計這一數字將急劇上升。抗藥性率的上升，加上創新抗菌藥物的匱乏以及人們對微生物群紊亂日益成長的擔憂，暴露了現有治療模式的重大缺陷。隨著精準抗菌治療在醫療保健系統中變得日益重要，噬菌體療法作為一種有前景的替代療法，再次引起人們的關注，有望用於治療複雜的抗藥性細菌感染疾病。

噬菌體療法利用天然存在的病毒選擇性地清除病原體，同時保護有益的微生物群，與頻譜抗生素相比，其作用機制截然不同，更具標靶性。噬菌體能夠在感染部位自我複製，破壞細菌生物膜，並隨著細菌抗藥性的出現而進化，這些特性使其具有明顯的治療優勢，尤其是在對抗持續性、復發性和多重抗藥性感染疾病。這些特性使噬菌體療法成為一種潛在的輔助治療手段，有望改變未來感染疾病治療的模式。

在監管機構日益重視、公共資金投入和產業策略投資的支持下，市場正從主導研究轉向快速發展的臨床和商業領域。多家生技公司正在開發基因改造噬菌體平台、病原體特異性噬菌體混合物和聯合治療，旨在提高療效、擴大標靶細菌範圍並最大限度地減少抗藥性的產生。隨著臨床證據的不斷增強和生產技術的日益成熟，噬菌體療法有望在下一代精準感染疾病療法中發揮日益重要的作用。

成長驅動力：支持市場擴張的因素

多重抗藥性細菌感染疾病的蔓延暴露了傳統抗生素的局限性，迫切需要創新型抗菌療法。抗藥性細菌相關死亡率的持續上升，加上抗生素治療失敗率的增加和新型抗生素的短缺，使得人們對基於噬菌體的療法產生了濃厚的興趣。噬菌體療法結合了病原體特異性作用機制、維持原有微生物群的能力以及對抗抗藥性菌株的潛力，被視為應對全球抗藥性細菌危機的一種很有前景的解決方案。

此外，合成生物學、基因組工程、生物資訊學和人工智慧驅動的噬菌體發現技術的快速發展正在改變下一代噬菌體療法的研發。先進的工程平台能夠設計最佳化的噬菌體混合物，並開發出對細菌具有更廣泛療效、更佳治療效果和更低抗藥性的基因改造噬菌體。這些創新正在縮短研發週期，提高生產一致性，並拓展個人化抗感染疾病療法的應用前景，從而增強投資者信心並加速市場成長。

市場挑戰：阻礙進展的主要障礙

缺乏全球統一的噬菌體療法監管路徑仍是限制市場成長的一大障礙。現有的核准架構主要針對傳統藥物，往往無法充分應對噬菌體產品高度適應性和高度特異性的特性。這種監管的不確定性增加了研發風險，延長了核准時間，並提高了合規要求，尤其是在客製化精準噬菌體療法領域。

此外，噬菌體療法的商業化生產需要嚴格控制生產流程，以確保產品的純度、效力和批間一致性。噬菌體固有的生物學變異性，加上對嚴格的品管和可擴展純化技術的需求，增加了生產的複雜性和成本。而對於需要靈活生產能力和快速交付的個人化噬菌體混合物（每個患者都需要不同的配方），這些挑戰又因這些需求而進一步加劇。

噬菌體療法市場：關鍵洞察

本報告詳細分析了噬菌體療法市場的現狀，並指出了該行業內的潛在成長機會，尤其從分銷商和通路合作夥伴的角度出發。主要觀點包括：

  • 策略夥伴關係正在加速噬菌體療法的研發。各公司正與學術機構、醫院和政府機構合作，以擴充噬菌體庫、檢驗臨床療效並支持監管申報，從而縮短研發週期並改善個人化噬菌體療法的臨床樣本獲取途徑。
  • 政府和不稀釋的資金支持不斷加強市場上的創新。公共機構正積極支持噬菌體療法項目，以此作為對抗抗菌素抗藥性（AMR）的措施。
  • BiomX 透過醫療技術聯盟 (MTEC) 從美國國防部 (DHA) 和海軍部獲得了約 4000 萬美元的未稀釋資金，以推進其針對金黃色葡萄球菌的噬菌體資金籌措計劃。
  • 私人投資正在支持噬菌體療法的後期臨床開發。例如，BiomX公司籌集了約1,200萬美元，用於推進其針對囊腫纖維化患者慢性病菌感染的BX004 IIb期臨床試驗。這反映了投資者對噬菌體療法的持續信心。
  • 產業重組正在增強噬菌體技術的實力。諸如BiomX收購Adaptive Phage Therapeutics (APT)等策略性收購，正在擴展知識產權、個人化噬菌體療法方面的專業知識和噬菌體庫資源，從而支持長期產品開發。
  • 臨床里程碑的達成提升了噬菌體療法商業化的前景。各公司正從同情用藥計畫轉向對照臨床試驗，BiomX公司已在其BX004的IIb期試驗中啟動了病患給藥。這反映了研發管線的成熟以及與監管機構合作的加強。

噬菌體療法的市場區隔

Roots Analysis 根據以下參數對全球噬菌體療法市場進行分類：

根據指示

  • 細菌性痢疾
  • 腸道感染疾病
  • 胃腸道感染疾病
  • 多種性行為感染
  • 人工關節感染疾病（PJI）
  • 尿道感染

透過行政途徑

  • 靜脈
  • 口服
  • 直腸
  • 局部的

透過目標細菌

  • 大腸桿菌
  • 銅綠假單胞菌
  • 沙門氏菌
  • 金黃色葡萄球菌
  • 鏈球菌
  • 其他

按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

噬菌體療法市場：關鍵細分市場分析

尿道感染領域正在推動噬菌體療法市場的發展。

根據我們的市場評估，尿道感染（ UTI）領域在噬菌體療法市場中佔最大佔有率。這一主導地位部分歸因於全球範圍內復發性和多重抗藥性尿道感染（尤其是由大腸桿菌引起的感染）的高發生率，以及越來越多的臨床證據支持噬菌體療法作為抗生素的輔助性治療或替代療法。

另一方面，預計在預測期內，假體關節感染疾病（PJI）領域的複合年成長率將最高。這一快速成長歸因於全球整形外科植入手術數量的增加，以及噬菌體能夠穿透並破壞傳統抗生素難以根除的細菌生物膜結構的獨特能力。

口服給藥方式佔最大的市場佔有率，而外用給藥方式的成長速度最快。

從給藥途徑來看，口服給藥目前佔噬菌體療法市場的大部分佔有率。腸溶包衣和微囊化噬菌體製劑的進步提高了噬菌體在胃部環境中的存活率，從而鞏固了這個市場主導地位。

另一方面，由於慢性傷口感染疾病、糖尿病足潰瘍和術後感染的盛行率不斷上升，預計局部用藥市場將以相對較高的複合年成長率成長。

北美持續引領市場，而亞太地區則成為成長最快的地區。

根據我們的市場預測，北美預計將在整個預測期內保持全球市場收入的最大佔有率。這一最大佔有率得益於其先進的臨床開發生態系統、穩健的資金籌措環境，以及Locus Biosciences、Adaptive Phage Therapeutics和Armata Pharmaceuticals等專業噬菌體療法公司的存在。

同時，預計到 2035 年，亞太地區的複合年成長率將更高。這一高成長率的促進因素包括抗菌素抗藥性 (AMR) 負擔日益加重、生物技術能力不斷增強，以及中國、印度、日本、韓國和澳洲等國政府對感染疾病控制的日益重視。

噬菌體療法市場主要公司示例

  • Adaptive Phage Therapeutics
  • ContraFect
  • Eliava BioPreparations
  • Micreos
  • NPO Microgen
  • Phagelux AgriHealth
  • Pherecydes Pharma

專家訪談和行業洞察

本研究中提出的觀點和見解是基於與多位相關人員的討論。本研究報告包含與以下產業相關人員的詳細訪談記錄：

  • 法國一家小型企業的執行長
  • 以色列小規模公司資料科學主管、資深總監
  • 法國，大型企業，專案負責人
  • 獨立顧問
  • 希臘一家中小企業的創辦人兼執行長
  • 瑞士中小企業聯合創始人兼執行長
  • 美國中型公司，財務總監
  • 美國小規模企業首席科學官
  • 美國小規模企業的共同創辦人
  • 美國某大型企業的研究員和資深研究員
  • 生產專家，葡萄牙小規模企業
  • 美國某大公司醫學教授
  • 獨立研究員

目錄

第1章：序言

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章摘要整理

第6章：引言

  • 章節概要
  • 噬菌體的歷史演變
  • 噬菌體生物學
  • 噬菌體療法簡介
  • 噬菌體療法的應用
  • 噬菌體療法的優勢
  • 噬菌體療法的局限性
  • 結論

第7章：噬菌體療法：市場概覽

  • 章節概要
  • 噬菌體療法：藥物開發平臺
    • 依發展階段分析
    • 按治療區域分析
    • 依研發階段和治療領域進行分析
    • 按目標菌株進行分析
    • 依目標疾病適應症進行分析
    • 依治療類型進行分析
    • 依給藥途徑分析
  • 關於噬菌體相關技術的信息

第8章：噬菌體療法：研發公司的現狀

  • 章節概要
  • 噬菌體療法：研發商名單

第9章：公司和製藥概覽

  • 章節概要
  • 適應性噬菌體療法
  • 以下列出的其他公司也有類似的詳細資訊（基於公開資訊）。
  • ContraFect
  • Eliava BioPreparations
  • Micreos
  • NPO Microgen
  • Phagelux
  • Pherecydes Pharma

第10章：臨床試驗分析

  • 章節概要
  • 研究範圍和調查方法
  • 噬菌體療法市場：臨床試驗分析

第11章 專利分析

  • 章節概要
  • 研究範圍和調查方法
  • 噬菌體療法：專利分析
  • 噬菌體療法：專利基準
  • 噬菌體療法：專利評估
  • 主要專利列表

第12章：出版品基準分析

  • 章節概要
  • 研究範圍和調查方法
  • 出版品基準

第13章：學術研究津貼分析

  • 章節概要
  • 研究範圍和調查方法
  • 噬菌體療法：學術研究津貼分析

第14章資金籌措與投資分析

  • 章節概要
  • 資金籌措類型
  • 噬菌體療法市場：資金籌措和投資清單
  • 結論

第15章夥伴關係與合作

  • 章節概要
  • 夥伴關係模式
  • 噬菌體療法：合作夥伴關係和合作項目列表

第16章：新創公司健康指標

  • 章節概要
  • 噬菌體藥物研發公司：新創公司
  • 新創公司基準分析

第17章：全球噬菌體療法市場

  • 章節概要
  • 先決條件和調查方法
  • 全球噬菌體療法市場：歷史趨勢（2022年至今）及預測（至2035年）
  • 市場成長根源分析觀點
  • 情境分析
  • 主要市場區隔

第18章：噬菌體療法市場（以適應症分類）

第19章：噬菌體療法市場（依給藥途徑分類）

第20章：噬菌體療法市場（以標靶細菌分類）

第21章：噬菌體療法市場（按地區分類）

第22章 結論

第23章：高階主管洞察

第24章附錄一：表格形式數據

第25章 附錄二：公司與組織列表

Product Code: RA100388

BACTERIOPHAGE THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global bacteriophage therapy market is estimated to grow from USD 66.5 million in the current year to USD 266.8 million by 2035, reflecting a compound annual growth rate (CAGR) of approximately 16.7% during the forecast period.

Bacteriophage Therapy Market - IMG1

Bacteriophage Therapy Market: Growth and Trends

The rapid rise of antimicrobial resistance (AMR) has accelerated the need for novel anti-infective strategies capable of addressing infections that no longer respond to conventional antibiotics. Notably, the World Health Organization estimates that AMR is directly associated with approximately 1.27 million deaths annually, a figure projected to rise sharply if left unaddressed. Escalating resistance rates, coupled with the limited availability of innovative antibacterial agents and growing concerns regarding microbiome disruption, have exposed significant gaps in existing treatment paradigms. As healthcare systems increasingly prioritize precision antimicrobial approaches, bacteriophage therapy has gained renewed attention as a promising alternative capable of addressing complex and drug-resistant bacterial infections.

Bacteriophage therapeutics employ naturally occurring viruses that selectively eliminate pathogenic bacteria while preserving beneficial microbial flora, offering a targeted mechanism of action that differs fundamentally from broad-spectrum antibiotics. Their ability to self-amplify at the infection site, disrupt bacterial biofilms and evolve alongside emerging bacterial resistance provides a distinct therapeutic advantage, particularly for persistent, recurrent and multidrug-resistant infections. These characteristics have positioned phage therapy as a complementary modality with the potential to reshape future infectious disease management.

The market has transitioned from an academically driven research field to a rapidly advancing clinical and commercial landscape, supported by increasing regulatory engagement, public-sector funding and strategic industry investment. Several biotechnology companies are advancing engineered phage platforms, pathogen-specific phage cocktails and combination therapies designed to improve efficacy, broaden bacterial coverage and minimize resistance development. As clinical evidence continues to strengthen and manufacturing technologies mature, bacteriophage therapeutics are expected to play an increasingly important role in the next generation of precision anti-infective therapies.

Growth Drivers: Factors Fueling Market Expansion

The growing prevalence of multidrug-resistant bacterial infections has exposed the limitations of conventional antibiotics, creating an urgent need for innovative antimicrobial modalities. The continued rise in AMR-related mortality, combined with increasing antibiotic treatment failures and the scarcity of novel antibacterial drugs, is accelerating interest in bacteriophage-based therapeutics. Their pathogen-specific mechanism of action, ability to preserve the native microbiome and potential to combat resistant bacterial strains position phage therapy as a promising solution for addressing the global AMR crisis.

Additionally, rapid progress in synthetic biology, genome engineering, bioinformatics and AI-enabled phage discovery is transforming the development of next-generation bacteriophage therapeutics. Advanced engineering platforms are enabling the design of optimized phage cocktails and genetically enhanced bacteriophages with broader bacterial coverage, improved therapeutic performance and reduced resistance potential. These innovations are shortening development timelines, improving manufacturing consistency and expanding opportunities for personalized anti-infective therapies, thereby strengthening investor confidence and accelerating market growth.

Market Challenges: Critical Barriers Hindering Progress

The absence of globally harmonised regulatory pathways for bacteriophage therapeutics remains a significant barrier to market growth. Existing approval frameworks are primarily tailored to conventional pharmaceuticals and often fail to accommodate the adaptive and highly specific nature of phage-based products. This regulatory uncertainty increases development risk, extends approval timelines and raises compliance requirements, particularly for customised and precision phage therapies.

Further, commercial-scale production of bacteriophage therapeutics requires highly controlled manufacturing processes to ensure product purity, potency and batch-to-batch consistency. The inherent biological variability of phages, coupled with the need for robust quality control and scalable purification technologies, increases production complexity and costs. These challenges are further amplified for personalised phage cocktails, where patient-specific formulations demand flexible manufacturing capabilities and rapid turnaround times.

Bacteriophage Therapy Market: Key Insights

The report delves into the current state of the bacteriophage therapy market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key insights include:

  • Strategic collaborations are accelerating bacteriophage therapeutic development. Companies are partnering with academic institutions, hospitals, and government organizations to expand phage libraries, validate clinical efficacy, and support regulatory submissions, thereby shortening development timelines and improving access to clinical samples for personalized phage therapy.
  • Government and non-dilutive funding continue to strengthen innovation in the market. Public agencies are actively supporting bacteriophage therapy programs to combat antimicrobial resistance (AMR).
  • BiomX has received approximately USD 40 million in non-dilutive funding from the US Defense Health Agency (DHA) and the Department of Navy through the Medical Technology Enterprise Consortium (MTEC) to advance its Staphylococcus aureus phage therapy programs.
  • Private investments are supporting late-stage clinical development of bacteriophage therapeutics. For instance, BiomX raised approximately USD 12 million to advance its BX004 Phase IIb program for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, reflecting sustained investor confidence in phage-based therapies.
  • Industry consolidation is strengthening bacteriophage technology capabilities. Strategic acquisitions, such as BiomX's acquisition of Adaptive Phage Therapeutics (APT), have expanded intellectual property, personalized phage therapy expertise, and phage bank resources, supporting long-term product development.
  • Clinical milestones are improving commercialization prospects for bacteriophage therapeutics. Companies are advancing from compassionate-use programs to controlled clinical trials, with BiomX initiating Phase IIb patient dosing for BX004, reflecting a maturing pipeline and stronger regulatory engagement.

Bacteriophage Therapy Market Segments

Roots Analysis segments the global bacteriophage therapy opportunity across the following parameters:

By Target Indication

  • Bacterial Dysentery
  • Enteric Infections
  • Gastrointestinal Infections
  • Multiple Infections
  • Prosthetic Joint Infection (PJI)
  • Urinary Tract Infections

By Route of Administration

  • Intravenous
  • Oral
  • Rectal
  • Topical

By Targeted Bacteria

  • Escherichia coli
  • Pseudomonas aeruginosa
  • Salmonella
  • Staphylococcus aureus
  • Streptococcus
  • Others

By Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Bacteriophage Therapy Market: Key Segments Insight

Urinary Tract Infections Segment Leads the Bacteriophage Therapy Market

Based on our market assessment, the urinary tract infections segment holds the highest share of the bacteriophage therapy market. This leadership is driven by the high global prevalence of recurrent and multidrug-resistant UTIs, particularly those caused by Escherichia coli, coupled with growing clinical evidence supporting phage therapy as an adjunct or alternative to antibiotics.

On the other hand, the prosthetic joint infection (PJI) segment is projected to witness the highest CAGR during the forecast period. This accelerated growth is attributed to the increasing volume of orthopedic implant procedures worldwide and the unique ability of bacteriophages to penetrate and disrupt bacterial biofilms that are difficult to eradicate using conventional antibiotics.

Oral Route Captures the Largest Share and Topical Segment to Register Fastest Growth

Based on route of administration, the oral segment currently captures the majority of the bacteriophage therapy market. This dominance is supported by advances in enteric-coated and microencapsulated phage formulations that improve phage survival through the gastric environment.

Meanwhile, the topical segment is likely to grow at a relatively higher CAGR, fueled by the rising prevalence of chronic wound infections, diabetic foot ulcers, and surgical site infections.

North America Maintains Market Leadership and Asia-Pacific Emerges as the Fastest-Growing Region

According to our market projections, North America is expected to retain the highest share of global market revenue through the forecast period. This highest share is driven by an advanced clinical development ecosystem, strong funding environment, and the presence of specialized phage therapy companies including Locus Biosciences, Adaptive Phage Therapeutics, and Armata Pharmaceuticals.

Meanwhile, Asia-Pacific is projected to grow at a higher CAGR through 2035. This highest growth is driven by rising AMR burden, expanding biotechnology capabilities, and growing government focus on infectious disease management across China, India, Japan, South Korea, and Australia.

Example Players in Bacteriophage Therapy Market

  • Adaptive Phage Therapeutics
  • ContraFect
  • Eliava BioPreparations
  • Micreos
  • NPO Microgen
  • Phagelux AgriHealth
  • Pherecydes Pharma

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Small Company, France
  • Senior Director, Head of Data-Science, Small Company, Israel
  • Project Leader, Very Large Company, France
  • Independent Consultant
  • Founder and Chief Executive Officer, Small Company, Greece
  • Co-Founder and Chief Executive Officer, Small Company, Switzerland
  • Chief Financial Officer, Mid-sized Company, US
  • Chief Scientific Officer, Small Company, US
  • Co-Founder, Small Company, US
  • Staff Scientist & Principal Investigator, Very Large Company, US
  • Production Specialist, Small Company, Portugal
  • Professor of Medicine, Very Large Company, US
  • Independent Researcher

BACTERIOPHAGE THERAPY MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bacteriophage therapy market, focusing on key market segments, including target indication, route of administration, targeted bacteria, and geographical regions.
  • Bacteriophage Therapy: Market Landscape: Historical evolution and biology of bacteriophages, applications, advantages, and limitations of bacteriophage therapy, along with an assessment of the drug pipeline by phase of development, therapeutic area, targeted bacterial strain, target disease indication, type of therapy, and route of administration.
  • Developer Landscape: A detailed assessment of the developer landscape, based on parameters such as year of establishment, company size, and location of headquarters.
  • Company and Drug Profiles: In-depth profiles of prominent players engaged in offering bacteriophage therapeutics, featuring information on company overview, financials, pipeline, and recent developments.
  • Clinical Trial Analysis: An analysis of registered clinical trials by registration year, enrolled patient population, trial status, trial phase, study design, type of sponsor / collaborator, and geography.
  • Patent Analysis: An analysis of patents filed / granted related to bacteriophage therapy, based on parameters such as publication year, application year, jurisdiction, CPC symbols, type of applicant, patent benchmarking, and patent valuation.
  • Publication Benchmarking Analysis: An analysis of scientific publications by year, article type, popular keywords, publishers, journals, and journal impact factor.
  • Academic Grants Analysis: An analysis of academic grants awarded, based on parameters such as year of award, amount awarded, administering institute, support period, and recipient organization.
  • Funding and Investments Analysis: A detailed analysis of funding instances and amounts raised, by year, type of funding, investor, and geography.
  • Partnerships and Collaborations: A detailed analysis of partnerships and collaborations, by year, type of partnership, therapeutic area, application area, and geography.
  • Start-up Health Indexing: A proprietary benchmarking framework for start-up developers, based on pipeline strength, pipeline maturity, indication diversity, patent count, funding amount, and partnership activity.
  • Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth, including a Penetration-Growth (P-G) Matrix across geographies.
  • Executive Insights: Verbatim transcripts of interviews held with CEOs, senior scientists, and independent researchers active in the bacteriophage therapy domain.

Key Questions Answered in this Report

  • Which are the leading companies in the bacteriophage therapy market?
  • Which target indication and targeted bacteria segment dominate the bacteriophage therapy market?
  • Which region dominates the bacteriophage therapy market, and which region is growing the fastest?
  • What are the key trends observed in the bacteriophage therapy market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by bacteriophage therapy developers?
  • What is the current and future market size, and what is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • Which companies are the most active in terms of clinical trials, patents, funding, and partnerships?

Reasons to Buy this Report

This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the Bacteriophage Therapy market.

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments, valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges, empowering data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector, and in understanding whether those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience, in order to tailor products or services effectively.
  • The report equips new entrants with the requisite information regarding this market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary Insights Pack
  • Complementary PPT Insights Pack
  • Complementary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Landscape
  • 5.2. Executive Summary: Market Trends
  • 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Historical Evolution of Bacteriophages
  • 6.3. Biology of Bacteriophages
  • 6.4. Introduction to Bacteriophage Therapy
  • 6.5. Applications of Bacteriophage Therapy
  • 6.6. Advantages of Bacteriophage Therapy
  • 6.7. Limitations of Bacteriophage Therapy
  • 6.8. Conclusion

7. BACTERIOPHAGE THERAPY: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Bacteriophage Therapy: Drug Pipeline
    • 7.2.1. Analysis by Phase of Development
    • 7.2.2. Analysis by Therapeutic Area
    • 7.2.3. Analysis by Phase of Development and Therapeutic Area
    • 7.2.4. Analysis by Targeted Bacterial Strain
    • 7.2.5. Analysis by Target Disease Indication
    • 7.2.6. Analysis by Type of Therapy
    • 7.2.7. Analysis by Route of Administration
  • 7.3. Information on Bacteriophage Related Technologies

8. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Bacteriophage Therapeutics: List of Developers
    • 8.2.1. Analysis by Year of Establishment
    • 8.2.2. Analysis by Company Size
    • 8.2.3. Analysis by Location of Headquarters
    • 8.2.4. Analysis by Company Size and Location of Headquarters
    • 8.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics

9. COMPANY AND DRUG PROFILES

  • 9.1. Chapter Overview
  • 9.2. Adaptive Phage Therapeutics*
    • 9.2.1. Company Overview
    • 9.2.2. Financial Information
    • 9.2.3. Pipeline Overview
    • 9.2.4. Recent Developments and Future Outlook
  • Similar details are presented for other companies mentioned below (based on information in the public domain)
  • 9.3. ContraFect
  • 9.4. Eliava BioPreparations
  • 9.5. Micreos
  • 9.6. NPO Microgen
  • 9.7. Phagelux
  • 9.8. Pherecydes Pharma

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Bacteriophage Therapy Market: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 10.3.3. Analysis by Trial Status
    • 10.3.4. Analysis by Trial Phase and Enrolled Patient Population
    • 10.3.5. Analysis by Study Design
    • 10.3.6. Analysis by Type of Sponsor / Collaborator
    • 10.3.7. Most Active Players: Analysis by Number of Registered Trials
    • 10.3.8. Regional Analysis
      • 10.3.8.1. Analysis by Number of Registered Trials
      • 10.3.8.2. Analysis by Enrolled Patient Population

11. PATENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Bacteriophage Therapy: Patent Analysis
    • 11.3.1. Analysis by Publication Year
    • 11.3.2. Analysis by Patent Application Year
    • 11.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
    • 11.3.4. Analysis by Geography
    • 11.3.5. Analysis by CPC Symbols
    • 11.3.6. Analysis by Type of Applicant
    • 11.3.7. Leading Players: Analysis by Number of Patents
  • 11.4. Bacteriophage Therapy: Patent Benchmarking
    • 11.4.1. Analysis by Patent Characteristics
  • 11.5. Bacteriophage Therapy: Patent Valuation
  • 11.6. List of Leading Patents

12. PUBLICATION BENCHMARKING ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
    • 12.2.1. Analysis by Year of Publication
    • 12.2.2. Analysis by Type of Article
    • 12.2.3. Analysis by Popular Keywords
    • 12.2.4. Popular Publishers: Analysis by Number of Publications
    • 12.2.5. Popular Journals: Analysis by Number of Publications
    • 12.2.6. Popular Journals: Analysis by Journal Impact Factor
    • 12.2.7. Publications: Timeline Analysis
  • 12.3. Publication Benchmarking

13. ACADEMIC GRANTS ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Bacteriophage Therapy: Academic Grant Analysis
    • 13.3.1. Analysis by Year of Grant Award
    • 13.3.2. Analysis by Amount Awarded
    • 13.3.3. Analysis by Administering Institute Center
    • 13.3.4. Analysis by Support Period
    • 13.3.5. Analysis by Funding Institute Center and Support Period
    • 13.3.6. Analysis by Type of Grant Application
    • 13.3.7. Analysis by Purpose of Grant Award
    • 13.3.8. Analysis by Activity Code
    • 13.3.9. Word Cloud Analysis: Emerging Focus Areas
    • 13.3.10. Analysis by Study Section Involved
    • 13.3.11. Popular NIH Departments: Analysis by Number of Grants
    • 13.3.12. Analysis by Type of Recipient Organization
    • 13.3.13. Prominent Program Officers: Analysis by Number of Grants
    • 13.3.14. Popular Recipient Organizations: Analysis by Number of Grants
    • 13.3.15. Regional Distribution of Recipient Organizations

14. FUNDING AND INVESTMENTS ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. Bacteriophage Therapy Market: List of Funding and Investments
    • 14.3.1. Analysis by Year of Investment
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
    • 14.3.5. Investors Analysis
    • 14.3.6. Regional Distribution by Amount Invested
  • 14.4. Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
    • 15.3.1. Analysis by Year of Partnership
    • 15.3.2. Analysis by Type of Partnership
    • 15.3.3. Analysis by Year of Partnership and Type of Partner
    • 15.3.4. Analysis by Therapeutic Area
    • 15.3.5. Analysis by Application Area
    • 15.3.6. Most Active Players: Analysis by Number of Partnerships
    • 15.3.7. Regional Analysis
      • 15.3.7.1. Intercontinental and Intracontinental Agreements

16. START-UP HEALTH INDEXING

  • 16.1. Chapter Overview
  • 16.2. Bacteriophage Therapeutics Developers: Start-ups
    • 16.2.1. Analysis by Location of Headquarters
  • 16.3. Benchmarking of Start-ups
    • 16.3.1. Analysis by Pipeline Strength
    • 16.3.2. Analysis by Pipeline Maturity
    • 16.3.3. Analysis by Indication Diversity
    • 16.3.4. Analysis by Number of Patents
    • 16.3.5. Analysis by Funding Amount
    • 16.3.6. Analysis by Partnership Activity
    • 16.3.7. Start-ups Health Indexing: Roots Analysis Perspective

17. GLOBAL BACTERIOPHAGE THERAPY MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 17.4. Roots Analysis Perspective on Market Growth
  • 17.5. Scenario Analysis
    • 17.5.1. Conservative Scenario
    • 17.5.2. Optimistic Scenario
  • 17.6. Key Market Segmentations

18. BACTERIOPHAGE THERAPY MARKET, BY TARGET INDICATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Bacteriophage Therapy Market: Distribution by Target Indication
    • 18.3.1. Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.2. Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.3. Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.4. Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.5. Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.6. Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 18.4. Data Triangulation and Validation

19. BACTERIOPHAGE THERAPY MARKET, BY ROUTE OF ADMINISTRATION

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Bacteriophage Therapy Market: Distribution by Route of Administration
    • 19.3.1. Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.2. Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.3. Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 19.3.4. Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 19.4. Data Triangulation and Validation

20. BACTERIOPHAGE THERAPY MARKET, BY TARGETED BACTERIA

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Bacteriophage Therapy Market: Distribution by Targeted Bacteria
    • 20.3.1. Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.2. Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.3. Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.4. Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.5. Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 20.3.6. Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 20.4. Data Triangulation and Validation

21. BACTERIOPHAGE THERAPY MARKET, BY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Bacteriophage Therapy Market: Distribution by Geographical Regions
    • 21.3.1. Bacteriophage Therapy Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 21.3.2. Bacteriophage Therapy Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 21.3.3. Bacteriophage Therapy Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 21.3.4. Bacteriophage Therapy Market in Rest of the World: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 21.4. Market Dynamics Assessment
    • 21.4.1. Penetration-Growth (P-G) Matrix
  • 21.5. Data Triangulation and Validation

22. CONCLUSION

23. EXECUTIVE INSIGHTS

24. APPENDIX I: TABULATED DATA

25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 Bacteriophage Therapeutics: Information on Developer, Phase of Development, Bacterial Target, Target Disease Indication, Therapeutic Area
  • Table 7.2 Bacteriophage Therapeutics: Information on Type of Therapy and Route of Administration
  • Table 7.3 Bacteriophage Therapeutics: Information on Bacteriophage Related Technologies
  • Table 8.1 Bacteriophage Therapeutics: List of Developers
  • Table 9.1 Eliava BioPreparations: Company Overview
  • Table 9.2 Eliava BioPreparations: Pipeline Overview
  • Table 9.3 Micreos: Company Overview
  • Table 9.4 Micreos: Pipeline Overview
  • Table 9.5 NPO Microgen: Company Overview
  • Table 9.6 NPO Microgen: Pipeline Overview
  • Table 9.7 ContraFect: Company Overview
  • Table 9.8 ContraFect: Pipeline Overview
  • Table 9.9 Adaptive Phage Therapeutics: Company Overview
  • Table 9.10 Adaptive Phage Therapeutics: Pipeline Overview
  • Table 9.11 Phagelux: Company Overview
  • Table 9.12 Phagelux: Pipeline Overview
  • Table 9.13 Pherecydes Pharma: Company Overview
  • Table 9.14 Pherecydes Pharma: Pipeline Overview
  • Table 11.1 List of Top CPC Sections
  • Table 11.2 List of Top CPC Symbols
  • Table 11.3 List of Top CPC Codes
  • Table 11.4 Patent Analysis: Summary of Benchmarking
  • Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 11.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 12.1 Publication Benchmarking: List of Top 50 Publications
  • Table 14.1 Bacteriophage Therapy: List of Funding and Investments, Since 2017
  • Table 14.2 Funding and Investment Analysis: Summary of Investment
  • Table 15.1 Bacteriophage Therapy: List of Partnerships and Collaborations, Since 2017
  • Table 24.1 Bacteriophage Therapy: Distribution by Phase of Development
  • Table 24.2 Bacteriophage Therapy: Distribution by Therapeutic Area
  • Table 24.3 Bacteriophage Therapy: Distribution by Phase of Development and Therapeutic Area
  • Table 24.4 Bacteriophage Therapy: Distribution by Targeted Bacterial Strain
  • Table 24.5 Bacteriophage Therapy: Distribution by Target Disease Indication
  • Table 24.6 Bacteriophage Therapy: Distribution by Type of Therapy
  • Table 24.7 Bacteriophage Therapy: Distribution by Route of Administration
  • Table 24.8 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
  • Table 24.9 Bacteriophage Therapeutics Developers: Distribution by Company Size
  • Table 24.10 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
  • Table 24.11 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Table 24.12 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
  • Table 24.13 Clinical Trial Analysis: Scope and Methodology
  • Table 24.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2010
  • Table 24.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2010
  • Table 24.16 Clinical Trial Analysis: Distribution by Trial Status
  • Table 24.17 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
  • Table 24.18 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
  • Table 24.19 Clinical Trial Analysis: Distribution by Study Design
  • Table 24.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 24.21 Most Active Players: Distribution by Number of Registered Trials
  • Table 24.22 Geographical Analysis: Distribution by Number of Registered Trials
  • Table 24.23 Geographical Analysis: Distribution by Enrolled Patient Population
  • Table 24.24 Patent Analysis: Distribution by Type of Patent
  • Table 24.25 Patent Analysis: Cumulative Distribution by Publication Year
  • Table 24.26 Patent Analysis: Cumulative Distribution by Patent Application Year
  • Table 24.27 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent and Patent Application
  • Table 24.28 Patent Analysis: Distribution by Geography
  • Table 24.29 Patent Analysis: Distribution by CPC Symbols
  • Table 24.30 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 24.31 Leading Industry Players: Distribution by Number of Patents
  • Table 24.32 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 24.33 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Table 24.34 Patent Analysis: Distribution by Patent Age
  • Table 24.35 Patent Valuation Analysis
  • Table 24.36 Publication Benchmarking Analysis: Cumulative Year-wise Trend, Since 2018
  • Table 24.37 Publication Benchmarking Analysis: Distribution by Type of Article
  • Table 24.38 Publication Benchmarking Analysis: Distribution by Popular Keywords
  • Table 24.39 Popular Publishers: Distribution by Number of Publications
  • Table 24.40 Popular Journals: Distribution by Number of Publications
  • Table 24.41 Popular Journals: Distribution by Journal Impact Factor
  • Table 24.42 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, Since 2017
  • Table 24.43 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), Since 2017
  • Table 24.44 Grant Analysis: Distribution by Administering Institute Center
  • Table 24.45 Grant Analysis: Distribution by Support Period
  • Table 24.46 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table 24.47 Grant Analysis: Distribution by Type of Grant Application
  • Table 24.48 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 24.49 Grant Analysis: Distribution by Activity Code
  • Table 24.50 Grant Analysis: Distribution by Study Section Involved
  • Table 24.51 Popular NIH Departments: Distribution by Number of Grants
  • Table 24.52 Grant Analysis: Distribution by Types of Recipient Organization
  • Table 24.53 Most Prominent Program Officers: Distribution by Number of Grants
  • Table 24.54 Popular Recipient Organization: Distribution by Number of Grants
  • Table 24.55 Grant Analysis: Regional Distribution of Recipient Organization
  • Table 24.56 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2017
  • Table 24.57 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), Since 2017
  • Table 24.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2017
  • Table 24.59 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, Since 2017
  • Table 24.60 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
  • Table 24.61 Most Active Investors: Distribution by Number of Instances
  • Table 24.62 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, Since 2017
  • Table 24.63 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2017
  • Table 24.64 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 24.65 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2017
  • Table 24.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2017
  • Table 24.67 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 24.68 Partnerships and Collaborations: Distribution by Application Area
  • Table 24.69 Most Active Players: Distribution by Number of Partnerships
  • Table 24.70 Partnerships and Collaborations: Regional Distribution
  • Table 24.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 24.72 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 24.73 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 24.74 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 24.75 Startup-Health Indexing: Distribution by Indication Diversity
  • Table 24.76 Startup-Health Indexing: Distribution by Number of Patents
  • Table 24.77 Startup-Health Indexing: Distribution by Funding Amount
  • Table 24.78 Start-up Health Indexing: Roots Analysis Perspective
  • Table 24.79 Start-up Health Indexing: Leading Companies
  • Table 24.80 Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Table 24.81 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
  • Table 24.82 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
  • Table 24.83 Global Bacteriophage Therapy Market: Distribution by Target Indication
  • Table 24.84 Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.85 Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.86 Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.87 Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.88 Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.89 Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.90 Global Bacteriophage Therapy Market: Distribution by Route of Administration
  • Table 24.91 Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.92 Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.93 Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.94 Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.95 Global Bacteriophage Therapy Market: Distribution by Targeted Bacteria
  • Table 24.96 Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.97 Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.98 Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.99 Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.100 Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.101 Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.102 Global Bacteriophage Therapy Market: Distribution by Geographical Regions
  • Table 24.103 Bacteriophage Therapy Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.104 Bacteriophage Therapy Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.105 Bacteriophage Therapy Market for Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 24.106 Bacteriophage Therapy Market for Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 6.1 History Timeline of Bacteriophage
  • Figure 6.2 Bacteriophage Replication Cycle
  • Figure 6.3 Advantages of Bacteriophage Therapy
  • Figure 6.4 Limitations of Bacteriophage Therapy
  • Figure 7.1 Bacteriophage Therapy: Distribution by Phase of Development
  • Figure 7.2 Bacteriophage Therapy: Distribution by Therapeutic Area
  • Figure 7.3 Bacteriophage Therapy: Distribution by Phase of Development and Therapeutic Area
  • Figure 7.4 Bacteriophage Therapeutics: Distribution by Targeted Bacterial Strain
  • Figure 7.5 Bacteriophage Therapeutics: Distribution by Target Disease Indication
  • Figure 7.6 Bacteriophage Therapeutics: Distribution by Type of Therapy
  • Figure 7.7 Bacteriophage Therapeutics: Distribution by Route of Administration
  • Figure 8.1 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
  • Figure 8.2 Bacteriophage Therapeutics Developers: Distribution by Company Size
  • Figure 8.3 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
  • Figure 8.4 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Figure 8.5 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
  • Figure 10.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2010
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2010
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
  • Figure 10.6 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
  • Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.10 Geographical Analysis: Distribution by Number of Registered Trials
  • Figure 10.11 Geographical Analysis: Distribution by Enrolled Patient Population
  • Figure 11.1 Patent Analysis: Distribution by Type of Patent
  • Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year
  • Figure 11.3 Patent Analysis: Cumulative Distribution by Patent Application Year
  • Figure 11.4 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent and Patent Application
  • Figure 11.5 Patent Analysis: Distribution by Geography
  • Figure 11.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 11.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 11.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 11.10 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 11.11 Patent Analysis: Distribution by Patent Age
  • Figure 11.12 Patent Valuation Analysis
  • Figure 12.1 Publication Benchmarking Analysis: Cumulative Year-wise Trend, Since 2018
  • Figure 12.2 Publication Benchmarking Analysis: Distribution by Type of Article
  • Figure 12.3 Publication Benchmarking Analysis: Distribution by Popular Keywords
  • Figure 12.4 Popular Publishers: Distribution by Number of Publications
  • Figure 12.5 Popular Journals: Distribution by Number of Publications
  • Figure 12.6 Popular Journals: Distribution by Journal Impact Factor
  • Figure 12.7 Timeline Analysis: Distribution by Article Type and Average Time to Publish
  • Figure 12.8 Timeline Analysis: Distribution by Journal Impact Factor and Average Time to Publish
  • Figure 12.9 Timeline Analysis: Distribution by Type of Article and Maximum Time to Publish
  • Figure 12.10 Timeline Analysis: Distribution by Journal Impact Factor and Maximum Time to Publish
  • Figure 12.11 Publication Benchmarking
  • Figure 13.1 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, Since 2017
  • Figure 13.2 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), Since 2017
  • Figure 13.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 13.4 Grant Analysis: Distribution by Support Period
  • Figure 13.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 13.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 13.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 13.8 Grant Analysis: Distribution by Activity Code
  • Figure 13.9 Word Cloud: Emerging Focus Areas
  • Figure 13.10 Grant Analysis: Distribution by Study Section Involved
  • Figure 13.11 Popular NIH Departments: Distribution by Number of Grants
  • Figure 13.12 Grant Analysis: Distribution by Types of Recipient Organization
  • Figure 13.13 Most Prominent Program Officers: Distribution by Number of Grants
  • Figure 13.14 Popular Recipient Organization: Distribution by Number of Grants
  • Figure 13.15 Grant Analysis: Regional Distribution of Recipient Organization
  • Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2017
  • Figure 14.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), Since 2017
  • Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2017
  • Figure 14.4 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, Since 2017
  • Figure 14.5 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
  • Figure 14.6 Most Active Investors: Distribution by Number of Instances
  • Figure 14.7 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, Since 2017
  • Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since 2017
  • Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2017
  • Figure 15.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2017
  • Figure 15.5 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 15.6 Partnerships and Collaborations: Distribution by Application Area
  • Figure 15.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 15.8 Partnerships and Collaborations: Regional Distribution
  • Figure 15.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 16.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 16.2 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 16.3 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 16.4 Startup-Health Indexing: Distribution by Indication Diversity
  • Figure 16.5 Startup-Health Indexing: Distribution by Number of Patents
  • Figure 16.6 Startup-Health Indexing: Distribution by Funding Amount
  • Figure 16.7 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 16.8 Start-up Health Indexing: Leading Companies
  • Figure 17.1 Global Bacteriophage Therapy Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 17.2 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
  • Figure 17.3 Global Bacteriophage Therapy Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
  • Figure 17.4 Global Bacteriophage Therapy Market: Distribution by Target Indication
  • Figure 18.1 Bacteriophage Therapy Market for Bacterial Dysentery, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.2 Bacteriophage Therapy Market for Enteric Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million) Figure 18.3 Bacteriophage Therapy Market for Gastrointestinal Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.4 Bacteriophage Therapy Market for Multiple Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.5 Bacteriophage Therapy Market for Prosthetic Joint Infection (PJI), Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.6 Bacteriophage Therapy Market for Urinary Tract Infections, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.1 Global Bacteriophage Therapy Market: Distribution by Route of Administration
  • Figure 19.2 Bacteriophage Therapy Market for Intravenous, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.3 Bacteriophage Therapy Market for Oral, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.4 Bacteriophage Therapy Market for Rectal, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.5 Bacteriophage Therapy Market for Topical, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.1 Global Bacteriophage Therapy Market: Distribution by Targeted Bacteria
  • Figure 20.2 Bacteriophage Therapy Market for Escherichia coli, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.3 Bacteriophage Therapy Market for Pseudomonas aeruginosa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.4 Bacteriophage Therapy Market for Salmonella, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.5 Bacteriophage Therapy Market for Staphylococcus aureus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.6 Bacteriophage Therapy Market for Streptococcus, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.7 Bacteriophage Therapy Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.1 Global Bacteriophage Therapy Market: Distribution by Geographical Regions
  • Figure 21.2 Bacteriophage Therapy Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.3 Bacteriophage Therapy Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.4 Bacteriophage Therapy Market for Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.5 Bacteriophage Therapy Market for Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 22.1 Concluding Remarks: Market Landscape
  • Figure 22.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 22.3 Concluding Remarks: Patent Analysis
  • Figure 22.4 Concluding Remarks: Publication Benchmarking Analysis
  • Figure 22.5 Concluding Remarks: Academic Grants Analysis
  • Figure 22.6 Concluding Remarks: Funding and Investment Analysis
  • Figure 22.7 Concluding Remarks: Partnerships and Collaborations
  • Figure 22.8 Concluding Remarks: Start-up Health Indexing
  • Figure 22.9 Concluding Remarks: Market Sizing and Opportunity Analysis